// App-Quantinova.ai

: Canadian Cancer Trials Group (CCTG) LY.17: A Randomized Phase II Study Evaluating Novel Salvage Therapy Pre-Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) - Outcome of Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (R-DICEP) Versus R-GDP

Researchers

Presenter

  • Douglas A. Stewart

Principal Investigators

  • Lois E. Shepherd

  • Jill J. Dudebout

  • Jean-Francois Larouche

  • Neil Chua

  • Tara Baetz

  • Michael Crump

  • Mona Shafey

  • Nizar Abdel-Samad

  • Sue Robinson

  • Isabelle Fleury

  • Deborah Marcellus

  • Pamela Skrabek

  • Jesse Kelly

  • Annette E. Hay

  • Bingshu Chen

  • John Kuruvilla

Medical Centers

  • University Health Network, Princess Margaret Cancer Center, Toronto, Canada

  • The Moncton Hospital, Moncton, Canada

  • Tom Baker Cancer Centre, University of Calgary, Calgary, Canada

  • Canadian Cancer Trials Group, Kingston, Canada

  • Princess Margaret Hospital, Toronto, Canada

  • Queen Elizabeth II Health Science Center, Halifax, Canada

  • Canadian Cancer Trials Group, Queen's University, Kingston, Canada

  • Hamilton Regional Cancer Center, Hamilton, CAN

  • Maisonneuve-Rosemont Hospital, Institute of Hematology, Oncology and Cell Therapy, Montreal University, Montreal, Canada

  • Queen's University, Kingston, CAN

  • Canadian Cancer Trials Group, Cancer Research Institute, Kingston, Canada

  • Cross Cancer Institute, University of Alberta, Edmonton, Canada

  • Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada

  • Tom Baker Cancer Centre, Calgary, Canada

  • Hôpital Enfant-Jésus, Centre Hospitalier Universitaire de Quebec, Quebec City, Canada

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Filgrastim

  • Etoposide

  • Etoposide phosphate

  • Cisplatin

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved